Cited by 272

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Global challenges in breast cancer detection and treatment

Barrios, Carlos H.·2022·The Breast

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.breast.2022.02.003

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. Siegel, 2018, CA Cancer J Clin, 68, 7
  2. Harford, 2011, Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all, Lancet Oncol, 12, 306, 10.1016/S1470-2045(10)70273-4 · DOI
  3. The Global Breast Cancer Initiative, 2021, A strategic collaboration to strengthen health care for non-communicable diseases, Lancet Oncology. Published Online March, 7
  4. Carioli, 2017, Trends and predictions to 2020 in breast cancer mortality in Europe, Breast, 36, 89, 10.1016/j.breast.2017.06.003 · DOI
  5. McTiernan, 2008, Breast Cancer prevention in countries with diverse resources, Cancer, 113, 2325, 10.1002/cncr.23829 · DOI
  6. The Global Breast Cancer Initiative, 2021, A strategic collaboration to strengthen health care for non-communicable diseases, Lancet Oncology. Published Online March, 7
  7. Rosa, 2020, The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115), Breast Cancer Res Treat, 183, 749, 10.1007/s10549-020-05831-y · DOI
  8. Lauby-Secretan, 2015, Breast-cancer screening— viewpoint of the IARC working group, N Engl J Med, 372, 2353, 10.1056/NEJMsr1504363 · DOI
  9. Anderson, 2014, Breast cancer—thinking globally, Science, 343, 1403, 10.1126/science.1253344 · DOI
  10. Unger-Saldaña, 2014, Challenges to the early diagnosis and treatment of breast cancer in developing countries, World J Clin Oncol, 5, 465, 10.5306/wjco.v5.i3.465 · DOI
  11. Shao, 2019, Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes, Curr Oncol, 26, e385, 10.3747/co.26.4713 · DOI
  12. Duggan, 2020, Cancer, 126, 2339, 10.1002/cncr.32891 · DOI
  13. Richards, 1999, Influence of delay on survival in patients with breast cancer: a systematic review, Lancet, 353, 1119, 10.1016/S0140-6736(99)02143-1 · DOI
  14. Goss, 2013, Planning cancer control in Latin America and the Caribbean, Lancet Oncol, 14, 391, 10.1016/S1470-2045(13)70048-2 · DOI
  15. Strasser-Weippl, 2015, Progress and remaining challenges for cancer control in Latin America, Lancet Oncol, 16, 1405, 10.1016/S1470-2045(15)00218-1 · DOI
  16. Cortes, 2020, Enhancing global access to cancer medicines, Ca Cancer J Clin, 70, 105
  17. Barrios, 2021, Challenge of incorporating new drugs for breast cancer in Brazil: a proposed framework for improving access to innovative therapies, JCO Global Oncol, 7, 474, 10.1200/GO.20.00566 · DOI
  18. Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383 · DOI
  19. Cameron, 2017, 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin Adjuvant (HERA) trial, Lancet, 389, 1195, 10.1016/S0140-6736(16)32616-2 · DOI
  20. Perez, 2014, Trastuzumab plus Adjuvant Chemotherapy for human epidermal growth factor receptor-2 positive breast cancer. Planned joint analysis for overall survival from NSABP B-31 and NCCTG N9831, J Clin Orthod, 32, 3744
  21. Onarheim, 2016, PLoS One Published: Mar, 30
  22. Barrios, 2021, Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward, Lancet Oncol, 22, 477, 10.1016/S1470-2045(21)00492-7 · DOI

Cited by

Sorted by citations

See all 272

Metadata

Authors
Barrios, C. H.
Venue
The Breast
Publisher
Elsevier BV
Published
2022-03
Volume
62
Pages
S3-S6
ISSN
0960-9776
Cited by
272
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global challenges in breast cancer detection and treatment. https://app.cochat.ai/papers/10.1016/j.breast.2022.02.003
The paper
Barrios, C. H. (2022). Global challenges in breast cancer detection and treatment. The Breast. https://doi.org/10.1016/j.breast.2022.02.003